Despite the known effectiveness of various interventional oncology (IO) procedures in many areas of cancer treatment, many continue to be overlooked in treatment guidelines due to evidence issues, say experts.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.
Intraoperative epidural analgesia, perioperative opioid and total dose of volatile agent appear to show some “clinically meaningful associations” with relapse-free survival (RFS) in children with solid organ tumour, particularly in paediatric sarcoma patients, according to a Singapore study. However, no statistically significant association exists between epidural use and an improved RFS.
The oral multikinase VEGFR*1, 2, and 3 inhibitor pazopanib failed to improve overall survival (OS) in advanced ovarian cancer patients who have not progressed following first-line chemotherapy, according to the results of the AGO-OVAR16** study.
The combination of gemcitabine plus S-1 (GS) is as good as gemcitabine plus cisplatin (GC), the current standard treatment for advanced biliary tract cancer (BTC), according to data from the phase III FUGA-BT trial (JCOG1113). However, the former does not require concomitant hydration therapy and should be considered a new treatment option for patients with advanced or recurrent BTC.
According to the results of a systematic review and network meta-analysis, osimertinib and gefitinib plus pemetrexed-based chemotherapy appear to be the best first-line treatments, as shown by their most favourable progression-free (PFS) and overall survival (OS), for patients with advanced epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC).
Adding the PD-L1 inhibitor atezolizumab to first-line platinum-based chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic urothelial carcinoma (mUC), according to the IMvigor130* study presented at the ESMO Congress 2019.
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.